stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio di Fase 1b/2, multicentrico, su vorasidenib in combinazione con temozolomide (TMZ) in partecipanti affetti da glioma con una mutazione dell’isocitrato deidrogenasi-1 (IDH1) o dell’isocitrato deidrogenasi-2 (IDH2)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
S095032-211
Codice EudraCT
2024-513738-39-00
Sponsor/Promotore
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER (I.R.I.S.)
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Oncologia 1
Principal Investigator

Regorafenib in pazienti con recidiva di meningioma grado 2 e 3: studio randomizzato, multicentrico di fase 2 (MIRAGE trial)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IOV-BT-1-2023 MIRAGE
Codice EudraCT
2024-510954-28
Sponsor/Promotore
IOV
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Sviluppo di un modello di intelligenza artificiale per l’ottimizzazione della terapia nei gliomi

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
GLIO-AI
Codice EudraCT
NP
Sponsor/Promotore
CRO di Aviano
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio di Fase I/II di NMS-03305293 + Temozolomide in pazienti adulti con glioblastoma ricorrente

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
PARPA-293-002
Codice EudraCT
2023-508318-41
Sponsor/Promotore
NERVIANO MEDICAL SCIENCES SRL
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Principal Investigator

Lomustine with or without reirradiation for first progression study of glioblastoma: a randomized phase III study (LEGATO)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
EORTC 2227-BTG (LEGATO)
Codice EudraCT
2023-505267-36-00
Sponsor/Promotore
EORTC
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio adiuvante randomizzato, in doppio cieco, controllato verso placebo, in soggetti affetti da glioblastoma primario di nuova diagnosi, volto a verificare l’efficacia e la sicurezza dell’acido 2-idrossioleico (2-OHOA) in associazione alla radioterapia e al trattamento di cura standard a base di temozolomide.

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
MIN003-1806
Codice EudraCT
2018-000365-37
Sponsor/Promotore
Laminar Pharmaceuticals
Tipologia
Sperimentale
Fase
II / III
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top